Novo Nordisk A/S (NOV.DE)

EUR 103.14

(-0.33%)

Total Debt Summary of Novo Nordisk A/S

  • Novo Nordisk A/S's latest annual total debt in 2023 was 3.62 Billion DKK , up 4.76% from previous year.
  • Novo Nordisk A/S's latest quarterly total debt in 2024 Q1 was 3.6 Billion DKK , down -0.29% from previous quarter.
  • Novo Nordisk A/S reported annual total debt of 3.45 Billion DKK in 2022, down -3.51% from previous year.
  • Novo Nordisk A/S reported annual total debt of 3.58 Billion DKK in 2021, up 157.51% from previous year.
  • Novo Nordisk A/S reported quarterly total debt of 3.6 Billion DKK for 2024 Q1, down -0.29% from previous quarter.
  • Novo Nordisk A/S reported quarterly total debt of 3.62 Billion DKK for 2023 FY, up 4.76% from previous quarter.

Annual Total Debt Chart of Novo Nordisk A/S (2023 - 2016)

Historical Annual Total Debt of Novo Nordisk A/S (2023 - 2016)

Year Total Debt Total Debt Growth
2023 3.62 Billion DKK 4.76%
2022 3.45 Billion DKK -3.51%
2021 3.58 Billion DKK 157.51%
2020 1.39 Billion DKK 131.91%
2019 599.93 Million EUR 769.31%
2018 69.01 Million EUR -69.67%
2017 227.52 Million EUR 638.75%
2016 30.79 Million EUR 0.0%

Peer Total Debt Comparison of Novo Nordisk A/S

Name Total Debt Total Debt Difference
BioNTech SE 219.1 Million EUR -1553.028%
CureVac N.V. 41.85 Million EUR -8552.452%
Biotest Aktiengesellschaft 689.8 Million EUR -425.049%
Biotest Aktiengesellschaft 689.8 Million EUR -425.049%
BRAIN Biotech AG 4.65 Million EUR -77637.393%
Formycon AG 29.48 Million EUR -12183.067%
Heidelberg Pharma AG 5.83 Million EUR -62008.564%
Medigene AG 2.95 Million EUR -122672.378%